Genmab licenses HuMax-IL8 to Cormorant Pharmaceuticals

Published: 30-May-2012
Ingredients Research & Development Pharmaceutical

Human antibody will be evaluated for the treatment of selected cancers


Genmab, a Danish developer of human antibody therapeutics for the treatment of cancer, has granted an exclusive, worldwide licence to its HuMax-IL8 antibody to Cormorant Pharmaceuticals.

Under the terms of the agreement, Genmab will receive an upfront payment of an undisclosed amount and will be entitled to milestone payments and royalties on net sales.

Cormorant will evaluate HuMax-IL8 for treatment of selected cancers and will be responsible for all future costs of developing, manufacturing and marketing HuMax-IL8.

‘We are pleased to enter this licence agreement with Cormorant Pharmaceuticals who will work towards resuming the development of HuMax-IL8,’ said Jan van de Winkel, chief executive of Genmab.

  • Companies:
  • Genmab
See more

You may also like

Regulatory

ImaginAb announces supply agreement with Genmab

Read more
The non-exclusive worldwide agreement provides Genmab a license to use the company’s CD8 ImmunoPET imaging technology

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  5. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

ImaginAb announces supply agreement with Genmab

The non-exclusive worldwide agreement provides Genmab a license to use the company’s CD8 ImmunoPET imaging technology
Research & Development

Genmab and Synaffix enter into ADC license agreement

Genmab will be responsible for the research, development, manufacturing and commercialisation of any resulting ADC therapies
Research & Development

Personalised cancer treatment 2.0: new combination strategy developed

Tumours often comprise groups of cancer cells that show differential drug sensitivities, one of the reasons that initially effective treatments usually do not lead to long-term benefit in patients
Ingredients

Tisotumab Vedotin co-developed by Genmab and Seattle Genetics

Genmab and Seattle Genetics announced Seattle Genetics has exercised its option to co-develop tisotumab vedotin
Research & Development

Genmab enters licensing agreement with Gilead for DuoBody technology

Gilead will develop a bispecific antibody with DuoBody technology
Research & Development

Novo Nordisk pays US$2m for access to Genmab technology

Two Danish firms will develop bispecific antibodies not related to cancer
Research & Development

Genmab teams up with BioNTech in immuno-oncology development and commercialisation agreement

Makes an upfront payment of US$10m to BioNTech
Subscribe now